| 孙蓉,宋绍霏,张通.阿尔茨海默病药物治疗的现状及展望[J].中国临床保健杂志,2020,23(2):153-156. |
| 阿尔茨海默病药物治疗的现状及展望 |
| Current situation and prospect of drug therapy for alzheimer′s disease |
| 投稿时间：2019-09-25 |
| DOI：10.3969/J.issn.1672-6790.2020.02.003 |
| 中文关键词: 阿尔茨海默病 药物疗法 综述 |
| 英文关键词: Alzheimer Disease Drug Therapy Review 〖FL |
| 基金项目: |
|
| 摘要点击次数: 4843 |
| 全文下载次数: 5842 |
| 中文摘要: |
| 阿尔茨海默病(AD)是一种神经系统退行性疾病。随着人口老龄化,发病率日益增加。根据中国疾控中心统计数据显示,2005—2016年的10余年里,因AD死亡的人数增长比例高达57.8%,预计到2050年全球AD痴呆患者将超过1亿。针对AD的药物治疗一直是研究热点,全世界范围内正在大规模开展抗AD新药的临床前筛选工作,然而,在所有类型AD治疗药物中,失败率均大于99%,而对于疾病修饰治疗(DMTs)失败率为100%。目前仅有五种药物被批准用于治疗,均为乙酰胆碱酯酶抑制剂和谷氨酸受体拮抗剂,且只能减缓症状,无法改变疾病进程。本文就阿尔茨海默病目前常用药物治疗、新药研发现状以及未来研发方向进行介绍。 |
| 英文摘要: |
| Alzheimer′s disease is a neurodegenerative disease with an increasing incidence as the population ages.According to statistics from the Chinese center for disease control and prevention,the number of people dying from Alzheimer′s disease increased by 57.8 percent during the past 10 years from 2005 to 2016.Unless a way is found to delay,prevent or treat AD,the number of dementia patients with AD worldwide is expected to exceed 100 million by 2050.Drug therapy for alzheimer′s disease has always been a research hotspot.Preclinical screening of new anti-AD drugs is being carried out on a large scale all over the world.However,the failure rate of all types of AD drugs is greater than 99%,while the failure rate of disease modified therapy (DMTs) is 100%.Only five drugs have been approved for treatment,namely acetylcholinesterase inhibitor and NMDA receptor antagonist,which can only relieve some symptoms,but cannot change the progress of the disease.Here we introduced the current situation of drug therapy,new drug development and future research of alzheimer′s disease. |
|
查看全文
|
| 关闭 |
|
|
|